- World Pharma News Home » Financial » Pharma Sector: Few Newsmakers Of The Week - Synta, Glaxo, Merck, Wyeth, Lilly, Medicis, Pipex
(a free service delivered by FeedBurner)
The first month of the New Year is already over. Here's what happened on the pharma turf in the week ended Feb.1, 2008.
With the incidence of melanoma rising more rapidly than any other cancer during the past ten years, there is an urgent need to develop new therapies in order to curb the increase in melanoma death rate. There are currently few treatment options for advanced melanoma, and none that can improve overall survival beyond the median 6 to 9 months. Elesclomol, which is being jointly developed by Synta and Glaxo - the first in a new class of cancer therapies called oxidative stress inducers, which kills only tumor cells is expected to have a major impact on the treatment of metastatic melanoma.
Discuss Add this link to... Bury
With the incidence of melanoma rising more rapidly than any other cancer during the past ten years, there is an urgent need to develop new therapies in order to curb the increase in melanoma death rate. There are currently few treatment options for advanced melanoma, and none that can improve overall survival beyond the median 6 to 9 months. Elesclomol, which is being jointly developed by Synta and Glaxo - the first in a new class of cancer therapies called oxidative stress inducers, which kills only tumor cells is expected to have a major impact on the treatment of metastatic melanoma.
Discuss Add this link to... Bury
Comments